3D-Wound healing model: Influence of morphine and solid lipid nanoparticles

Journal of Biotechnology

Volumn 148, Issue 1, 2010, Pages 24-30

  Küchler, Sarah ^a   Wolf, Nadine B ^a   Heilmann, Sarah ^a   Weindl, Günther ^a   Helfmann, Jürgen ^b   Yahya, Momin Mohd ^a   Stein, Christoph ^a   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Laser und Medizin Technologie GmbH   (Germany)

Author keywords

Alternatives to animal experiments; Morphine; Reconstructed full thickness skin; Solid lipid nanoparticles; UGT2B7; Wound healing model

Indexed keywords

ALTERNATIVES TO ANIMAL EXPERIMENTS; ANIMAL EXPERIMENTS; GLUCURONIDATION; HEALING PROCESS; KERATINOCYTE MIGRATION; KERATINOCYTES; LASER IRRADIATIONS; MEAN SIZE; NEW OPTIONS; OPIOIDS; RE-EPITHELIALIZATION; SKIN EQUIVALENTS; SOLID LIPID NANOPARTICLES; TARGET SITES; WOUND CLOSURE; WOUND DRESSINGS; WOUND HEALING; WOUND MANAGEMENT;

ANIMALS; CELL CULTURE; NANOPARTICLES;

THREE DIMENSIONAL;

MORPHINE; SOLID LIPID NANOPARTICLE; DELAYED RELEASE FORMULATION; GLUCURONOSYLTRANSFERASE; LIPID; NANOPARTICLE; UGT2B7 PROTEIN, HUMAN;

ARTICLE; CARBON DIOXIDE LASER; CONTROLLED STUDY; CYTOTOXICITY; DERMIS; EPITHELIZATION; FULL THICKNESS SKIN GRAFT; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; SKIN IRRITATION; WOUND CLOSURE; WOUND HEALING; ARTIFICIAL SKIN; BIOLOGICAL MODEL; CELL CULTURE; CYTOCHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FIBROBLAST; GENETICS; LASER; METABOLISM; PHARMACOLOGY; TOXICITY TESTING;

CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; FIBROBLASTS; GLUCURONOSYLTRANSFERASE; HISTOCYTOCHEMISTRY; HUMANS; KERATINOCYTES; LASERS; LIPIDS; MODELS, BIOLOGICAL; MORPHINE; NANOPARTICLES; SKIN, ARTIFICIAL; TOXICITY TESTS; WOUND HEALING;

ANIMALIA;

EID: 77953914789     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2010.01.001     Document Type: Article

References (65)

1. Ackermann, K., Lombardi Borgia, S., Korting, H.C., Mewes, K.R., Schäfer-Korting, M., in press. The Phenion®-Full Thickness Skin Model for Percutaneous Absorption Testing. Skin Pharmacol. Physiol.
2. Baron J.M., Holler D., Schiffer R., Frankenberg S., Neis M., Merk H.F., Jugert F.K. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J. Invest. Dermatol. 2001, 116:541-548.
3. Bigliardi-Qi M., Gaveriaux-Ruff C., Zhou H., Hell C., Bady P., Rufli T., Kieffer B., Bigliardi P. Deletion of delta-opioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 2006, 74:174-185.
4. Bigliardi-Qi M., Sumanovski L.T., Buchner S., Rufli T., Bigliardi P.L. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 2004, 209:183-189.
5. Bigliardi P.L., Bigliardi-Qi M., Buechner S., Rufli T. Expression of mu-opiate receptor in human epidermis and keratinocytes. J. Invest. Dermatol. 1998, 111:297-301.
6. Bigliardi P.L., Buchner S., Rufli T., Bigliardi-Qi M. Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists. J. Recept. Signal Transduct. Res. 2002, 22:191-199.
7. Bigliardi P.L., Sumanovski L.T., Buchner S., Rufli T., Bigliardi-Qi M. Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression. J. Invest. Dermatol. 2003, 120:145-152.
8. Braem C., Blaschke T., Panek-Minkin G., Herrmann W., Schlupp P., Paepenmüller T., Müller-Goyman C., Mehnert W., Bittl R., Schäfer-Korting M., Kramer K.D. Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. J. Control. Release 2007, 119:128-135.
9. Chouinard S., Yueh M.F., Tukey R.H., Giton F., Fiet J., Pelletier G., Barbier O., Belanger A. Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling. J. Steroid Biochem. Mol. Biol. 2008, 109:247-253.
10. Coffman B.L., Kearney W.R., Goldsmith S., Knosp B.M., Tephly T.R. Opioids bind to the amino acids 84 to 118 of UDP-glucuronosyltransferase UGT2B7. Mol. Pharmacol. 2003, 63:283-288.
11. Congiu M., Mashford M.L., Slavin J.L., Desmond P.V. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab. Dispos. 2002, 30:129-134.
12. Cuignet O., Mbuyamba J., Pirson J. The long-term analgesic efficacy of a single-shot fascia iliaca compartment block in burn patients undergoing skin-grafting procedures. J. Burn Care Rehabil. 2005, 26:409-415.
13. Cuignet O., Pirson J., Boughrouph J., Duville D. The efficacy of continuous fascia iliaca compartment block for pain management in burn patients undergoing skin grafting procedures. Anesth. Analg. 2004, 98:1077-1081.
14. Darbari D.S., van Schaik R.H., Capparelli E.V., Rana S., McCarter R., van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am. J. Hematol. 2008, 83:200-202.
15. DiPietro L.A. Wound healing: the role of the macrophage and other immune cells. Shock 1995, 4:233-240.
16. El Ghalbzouri A., Hensbergen P., Gibbs S., Kempenaar J., van der Schors R., Ponec M. Fibroblasts facilitate re-epithelialization in wounded human skin equivalents. Lab Invest. 2004, 84:102-112.
17. Falanga V., Isaacs C., Paquette D., Downing G., Kouttab N., Butmarc J., Badiavas E., Hardin-Young J. Wounding of bioengineered skin: cellular and molecular aspects after injury. J. Invest. Dermatol. 2002, 119:653-660.
18. Fang J.Y., Liu P.F., Huang C.M. Decreasing systemic toxicity via transdermal delivery of anticancer drugs. Curr. Drug Metab. 2008, 9:592-597.
19. Flock P. Pilot study to determine the effectiveness of diamorphine gel to control pressure ulcer pain. J. Pain Symptom Manage. 2003, 25:547-554.
20. Gysler A., Lange K., Korting H.C., Schäfer-Korting M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm. Res. 1997, 14:793-797.
21. Hassan A.H., Ableitner A., Stein C., Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 1993, 55:185-195.
22. Jenning V., Gysler A., Schäfer-Korting M., Gohla S.H. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 2000, 49:211-218.
23. Jenning V., Schäfer-Korting M., Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control Release. 2000, 66:115-126.
24. Küchler S., Radowski M.R., Blaschke T., Dathe M., Plendl J., Haag R., Schäfer-Korting M., Kramer K.D. Nanoparticles for skin penetration enhancement-a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2009, 71:243-250.
25. Lam C.F., Chang P.J., Huang Y.S., Sung Y.H., Huang C.C., Lin M.W., Liu Y.C., Tsai Y.C. Prolonged use of high-dose morphine impairs angiogenesis and mobilization of endothelial progenitor cells in mice. Anesth. Analg. 2008, 107:686-692.
26. Lancon A., Hanet N., Jannin B., Delmas D., Heydel J.M., Lizard G., Chagnon M.C., Artur Y., Latruffe N. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos. 2007, 35:699-703.
27. Laplante A.F., Germain L., Auger F.A., Moulin V. Mechanisms of wound reepithelialization: hints from a tissue-engineered reconstructed skin to long-standing questions. FASEB J. 2001, 15:2377-2389.
28. Liu J., Hu W., Chen H., Ni Q., Xu H., Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 2007, 328:191-195.
29. Lombardi Borgia S., Regehly M., Sivaramakrishnan R., Mehnert W., Korting H.C., Danker K., Röder B., Kramer K.D., Schäfer-Korting M. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release 2005, 110:151-163.
30. Lombardi Borgia S., Schlupp P., Mehnert W., Schäfer-Korting M. In vitro skin absorption and drug release-a comparison of six commercial prednicarbate preparations for topical use. Eur. J. Pharm. Biopharm. 2008, 68:380-389.
31. Luu-The V., Ferraris C., Duche D., Belanger P., Leclaire J., Labrie F. Steroid metabolism and profile of steroidogenic gene expression in Episkin: high similarity with human epidermis. J. Steroid Biochem. Mol. Biol. 2007, 107:30-36.
32. Manjunath K., Reddy J.S., Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp. Clin. Pharmacol. 2005, 27:127-144.
33. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
34. Müller R.H., Petersen R.D., Hommoss A., Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 2007, 59:522-530.
35. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54(Suppl. 1):S131-155.
36. Oesch F., Fabian E., Oesch-Bartlomowicz B., Werner C., Landsiedel R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab. Rev. 2007, 39:659-698.
37. Ohno S., Kawana K., Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab. Dispos. 2008, 36:688-694.
38. Perreault S., Choiniere M., du Souich P.B., Bellavance F., Beauregard G. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries. Ann. Pharmacother. 2001, 35:1588-1592.
39. Platzer M., Likar R., Stein C., Beubler E., Sittl R. Topical application of morphine gel in inflammatory mucosal and cutaneous lesions. Schmerz 2005, 19:296-301.
40. Poonawala T., Levay-Young B.K., Hebbel R.P., Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005, 13:165-174.
41. Projean D., Morin P.E., Tu T.M., Ducharme J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 2003, 33:841-854.
42. Rook J.M., Hasan W., McCarson K.E. Temporal effects of topical morphine application on cutaneous wound healing. Anesthesiology 2008, 109:130-136.
43. Rook J.M., Hasan W., McCarson K.E. Morphine-induced early delays in wound closure: involvement of sensory neuropeptides and modification of neurokinin receptor expression. Biochem. Pharmacol. 2009, 77:1747-1755.
44. Rook J.M., McCarson K.E. Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release. Biochem. Pharmacol. 2007, 74:752-757.
45. Salemi S., Aeschlimann A., Reisch N., Jungel A., Gay R.E., Heppner F.L., Michel B.A., Gay S., Sprott H. Detection of kappa and delta opioid receptors in skin-outside the nervous system. Biochem. Biophys. Res. Commun. 2005, 338:1012-1017.
46. Santos Maia C., Mehnert W., Schaller M., Korting H.C., Gysler A., Haberland A., Schäfer-Korting M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug Targeting 2002, 10:489-495.
47. Sassani J.W., Zagon I.S., McLaughlin P.J. Opioid growth factor modulation of corneal epithelium: uppers and downers. Curr. Eye Res. 2003, 26:249-262.
48. Säwe J., Svensson J.O., Rane A. Morphine metabolism in cancer patients on increasing oral doses-no evidence for autoinduction or dose-dependence. Br. J. Clin. Pharmacol. 1983, 16:85-93.
49. Schäfer-Korting M., Bock U., Diembeck W., Düsing H.J., Gamer A., Haltner-Ukomadu E., Hoffmann C., Kaca M., Kamp H., Kersen S., Kietzmann M., Korting H.C., Krächter H.U., Lehr C.M., Liebsch M., Mehling A., Müller-Goymann C., Netzlaff F., Niedorf F., Rübbelke M.K., Schäfer U., Schmidt E., Schreiber S., Spielmann H., Vuia A., Weimer M. The use of reconstructed human epidermis for skin absorption testing: results of the validation study. Altern. Lab. Anim. 2008, 36:161-187.
50. Shidhaye S.S., Vaidya R., Sutar S., Patwardhan A., Kadam V.J. Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr. Drug Deliv. 2008, 5:324-331.
51. Stecova J., Mehnert W., Blaschke T., Kleuser B., Sivaramakrishnan R., Zouboulis C.C., Seltmann H., Korting H.C., Kramer K.D., Schäfer-Korting M. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm. Res. 2007, 24:991-1000.
52. Stein C., Clark J.D., Oh U., Vasko M.R., Wilcox G.L., Overland A.C., Vanderah T.W., Spencer R.H. Peripheral mechanisms of pain and analgesia. Brain Res. Rev. 2009, 60:90-113.
53. Stone A.N., Mackenzie P.I., Galetin A., Houston J.B., Miners J.O. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos. 2003, 31:1086-1089.
54. Sun C., Di Rienzo A. UGT2B7 is not expressed in normal breast. Breast Cancer Res. Treat. 2009, 117:225-226.
55. Tateishi M., Ohashi K., Kobayashi K., Hashimoto T., Yamaguchi J., Fujioka H., Izawa K., Masada M. Interindividual variation in the ratio between plasma morphine and its metabolites in cancer patients. Int. J. Clin. Pharmacol. Res. 2003, 23:75-82.
56. Tegeder I., Lotsch J., Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin. Pharmacokinet. 1999, 37:17-40.
57. Thorn C.F., Klein T.E., Altman R.B. Codeine and morphine pathway. Pharmacogenet. Genomics 2009, 19:556-558.
58. Twillman R.K., Long T.D., Cathers T.A., Mueller D.W. Treatment of painful skin ulcers with topical opioids. J. Pain Symptom Manage. 1999, 17:288-292.
59. Vaughan M.B., Ramirez R.D., Brown S.A., Yang J.C., Wright W.E., Shay J.W. A reproducible laser-wounded skin equivalent model to study the effects of aging in vitro. Rejuvenation Res. 2004, 7:99-110.
60. Vinogradov V.A., Spevak S.E., Iarygin K.N., Korobov N.V., Solov'eva A.I. Opioid activity of peptides and wound healing of the skin. Biull. Eksp. Biol. Med. 1987, 104:89-91.
61. Wissing S.A., Kayser O., Müller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
62. Wolf N.B., Küchler S., Radowski M.R., Blaschke T., Kramer K.D., Weindl G., Kleuser B., Haag R., Schäfer-Korting M. Influences of opioids and nanoparticles on in vitro wound healing models. Eur. J. Pharm. Biopharm. 2009.
63. Zeppetella G., Paul J., Ribeiro M.D. Analgesic efficacy of morphine applied topically to painful ulcers. J. Pain Symptom Manage. 2003, 25:555-558.
64. Zeppetella G., Ribeiro M.D. Morphine in intrasite gel applied topically to painful ulcers. J. Pain Symptom Manage. 2005, 29:118-119.
65. zur Mühlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149-155.